Avenciguat

Avenciguat (BI-685509) is a potent and orally active sGC activator. Avenciguat restores cyclic guanosine monophosphate (cGMP) and improves functionality of nitric oxide (NO) pathways. Avenciguat can be used in research of chronic kidney disease (CKD) and diabetic kidney disease (DKD) [1].

Product Specifications

CAS Number

[1579514-06-9]

Product Name Alternative

BI-685509

UNSPSC

12352005

Target

Guanylate Cyclase

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/avenciguat.html

Purity

99.77

Solubility

DMSO : 2 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=C(OCC)N(C2=NC(C3=C(OCC4=CC=C5C(CCN(C6CCOCC6)C5)=C4C)C(C)=CC=C3)=CC=C2)N=C1)O

Molecular Formula

C34H38N4O5

Molecular Weight

582.69

References & Citations

[1]Reinhart GA, et, al. The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease. J Pharmacol Exp Ther. 2023 Mar;384 (3) :382-392.